CR20240019A - RECEPTORES DE CÉLULAS T RESTRINGIDAS A HLA DE CLASE II CONTRA RAS MUTADO (Divisional expediente 2020-0150) - Google Patents

RECEPTORES DE CÉLULAS T RESTRINGIDAS A HLA DE CLASE II CONTRA RAS MUTADO (Divisional expediente 2020-0150)

Info

Publication number
CR20240019A
CR20240019A CR20240019A CR20240019A CR20240019A CR 20240019 A CR20240019 A CR 20240019A CR 20240019 A CR20240019 A CR 20240019A CR 20240019 A CR20240019 A CR 20240019A CR 20240019 A CR20240019 A CR 20240019A
Authority
CR
Costa Rica
Prior art keywords
restricted
hla class
cell receptors
mutated ras
tcr
Prior art date
Application number
CR20240019A
Other languages
English (en)
Inventor
Rami Yoseph
Paul F Robbins
Steven A Rosenberg
Gal Cafri
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of CR20240019A publication Critical patent/CR20240019A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464464—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Abstract

Se describe un receptor de células T aislado o purificado (TCR), en donde el TCR tiene especificidad antigénica para el homólogo de oncogén viral de sarcoma de rata Kirsten mutado (KRAS) presentado por una molécula de clase II de antígeno leucocitario humano (HLA). También se proporcionan proteínas y polipéptidos relacionados, así como ácidos nucleicos, vectores de expresión recombinantes, células huésped, poblaciones de células y composiciones farmacéuticas relacionados. También se describen métodos para detectar la presencia de cáncer en un mamífero y métodos para tratar o prevenir el cáncer en un mamífero
CR20240019A 2017-09-20 2018-09-19 RECEPTORES DE CÉLULAS T RESTRINGIDAS A HLA DE CLASE II CONTRA RAS MUTADO (Divisional expediente 2020-0150) CR20240019A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762560930P 2017-09-20 2017-09-20
PCT/US2018/051641 WO2019060349A1 (en) 2017-09-20 2018-09-19 CLASS II HLA RESTRICTED T LYMPHOCYTE RECEPTORS AGAINST KRAS MUTATED

Publications (1)

Publication Number Publication Date
CR20240019A true CR20240019A (es) 2024-02-15

Family

ID=63963389

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240019A CR20240019A (es) 2017-09-20 2018-09-19 RECEPTORES DE CÉLULAS T RESTRINGIDAS A HLA DE CLASE II CONTRA RAS MUTADO (Divisional expediente 2020-0150)

Country Status (17)

Country Link
US (2) US11306132B2 (es)
EP (1) EP3684799A1 (es)
JP (1) JP7256794B2 (es)
KR (1) KR20200051804A (es)
CN (1) CN111201237A (es)
AR (1) AR112902A1 (es)
AU (1) AU2018335274A1 (es)
BR (1) BR112020005469A2 (es)
CA (1) CA3076339A1 (es)
CR (1) CR20240019A (es)
EA (1) EA202090652A1 (es)
IL (1) IL273254A (es)
MA (1) MA50180A (es)
MX (1) MX2020003117A (es)
SG (1) SG11202002425PA (es)
TW (1) TWI825029B (es)
WO (1) WO2019060349A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
WO2020154617A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
MX2022010191A (es) * 2020-02-19 2022-11-14 Aelin Therapeutics Moleculas dirigidas a proteina ras mutante.
CA3169086A1 (en) * 2020-02-26 2021-09-02 Noam LEVIN Hla class ii-restricted t cell receptors against ras with g12v mutation
US20230312672A1 (en) * 2020-06-24 2023-10-05 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class i-restricted t cell receptors against cd20
EP4178976A1 (en) * 2020-07-13 2023-05-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class ii?restricted drb t cell receptors against ras with g12d mutation
CN116348484A (zh) * 2020-07-16 2023-06-27 美国卫生和人力服务部 针对含有g12v突变的ras的hla-ii类限制性drb t细胞受体
CN112300269B (zh) * 2020-09-29 2022-12-09 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途
EP4253410A1 (en) * 2020-11-24 2023-10-04 Shanghai Genbase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
CN114835800B (zh) * 2022-05-27 2023-10-13 重庆医科大学 Tcr或其抗原结合片段及其应用
WO2024072954A1 (en) * 2022-09-29 2024-04-04 Jerome Canady Research Institute for Advanced Biological and Technological Sciences Cold atmopsheric plasma treated pan-cancer epitope peptide within the collagen type vi a-3 (col6a3) protein as cancer vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545204B1 (en) 2002-09-06 2016-08-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
JP6686008B2 (ja) * 2014-10-02 2020-04-22 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
EP3223850B1 (en) * 2014-11-26 2020-01-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-mutated kras t cell receptors
MX2018000777A (es) * 2015-07-22 2018-03-23 Araxes Pharma Llc Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
MX2018003062A (es) * 2015-09-15 2018-09-11 Us Health Receptores de celula t que reconocen kras mutante restringido en hla-cw8.
HRP20221183T1 (hr) 2016-08-02 2022-12-09 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services T-stanični receptori anti-kras-g12d

Also Published As

Publication number Publication date
IL273254A (en) 2020-04-30
CA3076339A1 (en) 2019-03-28
AU2018335274A1 (en) 2020-04-09
MX2020003117A (es) 2020-08-20
TWI825029B (zh) 2023-12-11
US20220204584A1 (en) 2022-06-30
AR112902A1 (es) 2019-12-26
US20190085046A1 (en) 2019-03-21
BR112020005469A2 (pt) 2020-09-29
MA50180A (fr) 2021-05-26
CN111201237A (zh) 2020-05-26
WO2019060349A1 (en) 2019-03-28
KR20200051804A (ko) 2020-05-13
EP3684799A1 (en) 2020-07-29
JP2020534828A (ja) 2020-12-03
JP7256794B2 (ja) 2023-04-12
SG11202002425PA (en) 2020-04-29
EA202090652A1 (ru) 2020-08-21
TW201920251A (zh) 2019-06-01
US11306132B2 (en) 2022-04-19

Similar Documents

Publication Publication Date Title
CR20240019A (es) RECEPTORES DE CÉLULAS T RESTRINGIDAS A HLA DE CLASE II CONTRA RAS MUTADO (Divisional expediente 2020-0150)
SA518391109B1 (ar) Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ
MX2017006865A (es) Receptores de células t de kras anti-mutado.
CR20200287A (es) Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
AU2021203746B2 (en) T cell receptors recognizing MHC class II-restricted MAGE-A3
CY1122790T1 (el) Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις
CR20200170A (es) Receptores de células t que reconocen p53 mutado
CY1124176T1 (el) Προβλεψη ανοσογονiκοτητας των επιτοπων των t κυτταρων
PH12018501335A1 (en) Novel generation of antigen-specific tcrs
EA202092044A1 (ru) Химерные рецепторы антигена против cd33 и их применения
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
CA2848209C (en) T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
MX2019003445A (es) Proteinas de fusion inmunomoduladoras.
JP2015535816A5 (es)
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
BR112014008849A2 (pt) receptores quiméricos de antígeno anti-cd22
CY1123520T1 (el) Μεθοδοι για την προβλεψη της χρησιμοτητας των νεων αντιγονων για ανοσοθεραπεια
MX2022010157A (es) Receptores de células t restringidos a hla clase ii contra ras con mutación g12v.
MX2022009825A (es) Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
TR201905447T4 (tr) Yeni mhc bağımsız tümörle ilişkili antijenler.
CL2022002208A1 (es) Receptor de células t restringido por hla de la clase i contra ras con mutación
EP4230649A3 (en) Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
MX2017005644A (es) Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas.
US20170106066A1 (en) Engineered invariant chain molecule for improved mhc class i loading